Systematic Reviews
Copyright ©The Author(s) 2023.
World J Crit Care Med. Mar 9, 2023; 12(2): 71-88
Published online Mar 9, 2023. doi: 10.5492/wjccm.v12.i2.71
Table 4 Multiple logistic regression analysis to predict 30 d mortality
Feature
CytoSorb 300[84,85,86]
Jafron HA-series (80, 130, 180, 230, 280, 330, 380)[87]
Biosky MG-Series[88]
ManufacturerCytoSorbents™ Inc, United StatesJafron Biomedical Co., Ltd. No. 98, Technology Sixth Road, High-tech Zone, Zhuhai City, 519085, Guangdong, ChinaBiosun Medical Technology Co. Ltd, China
IFU versionOctober 1, 2021[87]11-Sep-191-Aug-18
AdsorbentCrosslinked DivinylbenzeneNeutral Macroporous ResinMedical Neutral Macroporous Synthetic Resin
Coating PolyvinylpyrollidoneCollodionNo data
Adsorbent Surface> 45000 m2 100000m2 No data
Storage fluidIsotonic salineWater for injectionSterile water
Use time/cartridge24 h, Can be administered up to 7 consecutive daysDepending on mode of operation: Hemoperfusion 100-250 mL/ min; Dialysis < 320 ml/ min with use upto 4 h; CRRT 150-250 mL/min with use upto 12 h; CPB up to 700 mL/ min with use upto 2.5 h120-180 min, Not suggested to use more than 3 times within 24 h
Blood flow100-700 mL/min, Recommended > 150 mL/min100-700 mL/min100-400 mL/min; Highest rate is 250 mL/min
Pmax760 mmHg750 mmHg750 mmHg
Mode of operation coveredHemoperfusion, Intermittent hemodialysis, CRRT, Cardiopulmonary bypass (CPB) ECMOHemoperfusion; Hemodialysis; CRRT; CPBHemoperfusion; Hemodialysis; CRRT; CPB only as comment in anticoagulation, not in setup
Shelf life3 yr2 yr2 yr
Safety report statusAs of 2021: > 162000 treatments distributed without confirmed serious device related eventsNo dataNo data